|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅱ study of arsenic trioxide in patients with relapsed or refractory multiple myeloma显示文摘 | Hussein M A Saleh M Ravandi F | 2004 | Br J Haematol2004，125，4： | 1 |
| 2 | Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System显示文摘 | Kantarjian H O'Brien S Ravandi F | | 0，，： | 1 |
| 3 | Efficacy of tosedostat,a novel,oral agent for elderly patients with relapsed or refractory acute myeloid leukemia:a review of the Phase II OPAL trial显示文摘 | Mathisen MS Ravandi F | | 0，，04： | 1 |
| 4 | Clofarabine plus low- dose Cytarabine followed by Clofarabine plus low-dose Cytarabine alternating with Decitabine in AML frontline therapyof older patients 显示文摘 | Faded A Ravandi F Huang X | 2012 | Cancer2012，118，18： | 1 |
| 5 | Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations显示文摘 | Loghavi S Zuo Z Ravandi F | 2014 | J Hematol Oncol2014，7，1： | 1 |
| 6 | Intensive chemotherapy does not benefit most older patients( age 70 years or older)with acute myeloid leukemia显示文摘 | Kantariian H Ravandi F O'Brien S | 2010 | Blood2010，116，22： | 1 |
| 7 | A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myeiodysplastic syndrome显示文摘 | Faderl S Ravandi F Huang X | 2008 | Blood2008，112，5： | 1 |
| 8 | Effective treatment of acute promy-elocytic leukemia with all-trans retinoic acid,arsenic trioxide,and gemtuzumab ozogamicin显示文摘 | Ravandi F Estey E Jones D | | 0，，： | 1 |
| 9 | Eradication of leukemia stem cells as a new goal of therapy in ceukemia 显示文摘 | Ravandi F Estrov Z | 2006 | Clin Cancer Res2006，12，2： | 1 |
| 10 | Activity of decitabine in the treatment of patients with chronic myelomonocytic leukemia显示文摘 | Aribi A Borthakur G Ravandi F | 2007 | Cancer2007，109，4： | 1 |
| 11 | Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin 显示文摘 | Ravandi F Estey E Jones D | 2009 | J Clin Oncol2009，27，4： | 1 |
| 12 | Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid,Arsenic trioxide,and gemtuzumab ozogamicin显示文摘 | Ravandi F Estey E Jones D | | 0，，04： | 1 |
| 13 | Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance显示文摘 | Ravandi F Kantarjian HM Talpaz M | 2001 | Cancer2001，91，11： | 1 |
| 14 | Cellular signaling pathways: new targets in leukaemia therapy显示文摘 | Ravandi F Talpaz M Kantarjian H | 2002 | Br J Haematol2002，116，1： | 1 |
| 15 | Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mu- tant AML in first relapse显示文摘 | Levis M Ravandi F Wang ES | 2011 | Blood2011，117，12： | 1 |
| 16 | Phase I/II study of combi- nation therapy with sorafenib,idambicin,and cytarabine in youn- ger patients with acute myeloid leukemia显示文摘 | Ravandi F Cortes JE Jones D | 2010 | J Clin Oncol2010，28，11： | 1 |
| 17 | Prognostic fac- tors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine 显示文摘 | Jabbour E Garcia-Manero G Ravandi F | 2013 | Clin Lymphoma Myeloma Leuk2013，13，2： | 1 |
| 18 | Advances in treatment of chronic myelogenous leukemia - new treatment options with tyrosine kinase inhibitors 显示文摘 | SANTOS F P RAVANDI F | 2009 | Leuk Lymphoma2009，50，2： | 1 |
| 19 | Activity of decitabine in patients with myelodys-plastic syndrome previously treated with azacitidine显示文摘 | Borthakur G Ahdab SE Ravandi F | 2008 | Leuk Lymphoma2008，49，4： | 1 |
| 20 | Phase Ⅱ study of arsenic trioxide in patients with relapsed or refractory multiple myeloma显示文摘 | Hussein MA Saleh M Ravandi F | 2004 | Br J Haematol2004，125，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员